Loading stock…

CSPC Pharmaceutical Group Limited (1093) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

CSPC Pharmaceutical Group Limited

1093Market cap $14BPrice $1.2

Country🇨🇳China

SectorHealthcare

IndustryPharmaceuticals

CSPC develops and manufactures generic and innovative drugs across oncology, cardiovascular, and neurology, dominating China's vitamin C and antibiotics markets. It's one of China's largest pharma players, betting big on R&D to shift from bulk drugs to high-margin, innovative treatments.

In Bastion Portfolios?

52W Return+7%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-6%1

Revenue Forecast

Rev CAGR (1y)+30%9

Rev CAGR (3y)+7%5

Rev CAGR (5y)+6%5

Earnings Forecast

EPS Growth Y+1+126%10

EPS Growth Y+2-34%2

EPS Growth Y+3+11%7

Quality

Margins

EBIT Margin28%9

Net Income Margin24%8

Free Cash Flow Margin38%10

Debt

Net Debt/EBITDA-1.810

Efficiency

ROE21%8

ROA15%9

Earnings Stability55

GEAR+VERY STRONG93

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)156

P/E Ratio (Forward 3y)155

P/BV2.56

EV Multiples

EV/EBITDA Fwd79

EV/EBIT Fwd79

Yield

Free Cash Flow Yield12.5%10

Dividend Yieldna–

Momentum

Short term

1 month return+4%9

3 month return+25%10

YTD return+19%7

Mid term

Price vs 52wHigh88%8

1 year return+4%5

Long term

3 year return+100%7

5 year return+26%5

Risk Shield

Price Risk

Beta0.76

Volatility47%3

Free Cash Flow

Free Cash Flow Margin38%10

Free Cash Flow Yield12.5%10

Quality

ROCE23%9

Earnings Stability55

Net Debt/EBITDA-1.810

02Growth

Is it actually growing, and how fast?

1093CSPC Pharmaceutical Group

Revenue FY25$3.7B

GROWTH RATING↗

AVERAGE49 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-6%1

Revenue, next 1Y+30%9

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+6%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+126%10

EPS growth, FY27E-34%2

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 7%/yr from here.

WATCH

A mid-pack grower, ahead of 49% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, a little ahead of the market.6/10

Over five years revenue is set to grow 6%/yr, about average versus companies worldwide.5/10

Earnings are set to grow in step with sales (EPS about 11%/yr vs revenue 7%/yr). One year dips: EPS falls 34% in year 2.

WEAKNESSES

Revenue fell 6%/yr over the last 3 years, behind 90% of companies worldwide.1/10

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

1093CSPC Pharmaceutical Group

Total return Current169%

Price return Current117%

MOMENTUM RATING↗

STRONG81 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+4%9

3-month return+25%10

YTD return+19%7

MID & LONG-TERM▾SCORE

% of 52-week high88%8

1-year return+4%5

3-year return+100%7

5-year return+26%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 4% over the past year, but 12% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+4%), over three months (+25%) and so far this year (+19%).

WATCH

Average long-term results. Multi-year returns are middling (+100% over three years and +26% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on CSPC Pharma. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

1093CSPC Pharmaceutical Group

Revenue FY25$3.7B

GROWTH RATING↗

AVERAGE49 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-6%1

Revenue, next 1Y+30%9

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+6%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+126%10

EPS growth, FY27E-34%2

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 7%/yr from here.

WATCH

A mid-pack grower, ahead of 49% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, a little ahead of the market.6/10

Over five years revenue is set to grow 6%/yr, about average versus companies worldwide.5/10

Earnings are set to grow in step with sales (EPS about 11%/yr vs revenue 7%/yr). One year dips: EPS falls 34% in year 2.

WEAKNESSES

Revenue fell 6%/yr over the last 3 years, behind 90% of companies worldwide.1/10

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

1093CSPC Pharmaceutical Group

Total return Current169%

Price return Current117%

MOMENTUM RATING↗

STRONG81 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+4%9

3-month return+25%10

YTD return+19%7

MID & LONG-TERM▾SCORE

% of 52-week high88%8

1-year return+4%5

3-year return+100%7

5-year return+26%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 4% over the past year, but 12% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+4%), over three months (+25%) and so far this year (+19%).

WATCH

Average long-term results. Multi-year returns are middling (+100% over three years and +26% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on CSPC Pharma. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community